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Pancreatic adenocarcinoma is a common disease considered to be poorly responsive to antiblastic treatment. Recent clinical and
preclinical results suggest that a combined treatment of gemcitabine (GEM), 5-flurouracil (5-FU) and folinic acid (FA) offers a clinical
benefit in patients with advanced pancreas adenocarcinoma. The aim of this phase II clinical trial was to evaluate the antitumour
activity and toxicity of a novel biweekly schedule of this combination in patients with pancreatic adenocarcinoma. A total of 42
patients received a 30min infusion of FA (100mgm
 2) and 5-FU (400mgm
 2) (FUFA) on days 1–3, and GEM 1000mgm
 2 on day
1 every 15 days. We observed 13 objective responses (two complete, 11 partial) and 23 stable diseases. The median time to
progression was 9.75 months (95% Confidence Interval (CI), 6.88–12.62) and the median overall survival was 13.10 months (95% CI
9.64–16.56). There were seven cases of each grade III gastroenteric and haematological toxicity. The GEM plus FUFA combination
appears to be well tolerated and very active in patients with pancreatic carcinoma.
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Pancreatic adenocarcinoma is one of the most detrimental
gastroenteric malignancies and the fourth–fifth leading cause of
death from malignancies in Western countries (Silverberg et al,
1990; Bramhall et al, 1995; Rocha Lima and Centeno, 2002).
Radical surgery in the low-stage disease is considered the only
chance of cure, but applies to less than 5% of the patients;
unfortunately, the majority of them are in an advanced stage at the
time of the diagnosis and only palliative therapies can be adopted
with minimal or no impact on the survival which remains very
poor (Bakkevold et al, 1992; Bramhall et al, 1995; Rosewicz and
Wiedenmann, 1997; Rocha Lima and Centeno, 2002).
Chemotherapy has long been considered largely ineffective, but
a cautious optimism has recently been expressed since the
discovery of new drugs such as gemcitabine (GEM), a fluorinated
nucleoside, which used alone or in combination with 5-fluorour-
acil (5-FU), has been considered effective in terms of antitumour
activity and palliation in these patients (Cohen et al, 2002;
Heinemann, 2002; Jacobs, 2002; Oettle and Riess, 2002; Evans et al,
2001). Both 5-FU and GEM are fluoropyrimidine prodrugs that
need to be converted to cytotoxic metabolites in the tumour cells
in order to exert their antitumour activity; several authors have
proposed that the two drugs may interact along their respective
pathways of activation leading to a synergistic antitumour activity
against a number of different malignancies (including pancreatic
carcinoma) in vitro and in vivo (Plunkett et al, 1996; Allegra and
Grem, 1997; Hidalgo et al, 1997, 1999; Berlin et al, 1998–99;
Correale et al, 1999; Schulz et al, 1998; Chu et al, 2001), and for this
reason the combination of the two drugs has been investigated in a
number of clinical trials in patients with advanced pancreatic
carcinoma (Grem, 1996; Hidalgo et al, 1997, 1999; Berlin et al,
1998–99, 2002; Cascinu et al, 1999; Correale et al, 2000; Oettle and
Riess, 2002). In previous studies of our groups, we demonstrated
that GEM affects 5-FU pharmacodynamics (Correale et al, 1999)
and pharmacokinetics, (Correale et al, 2003) and determines
synergic antitumour activity in vitro (Correale et al, 1999). The
results of a previous phase I–II clinical trial involving patients
with different malignancies (including pancreas and colorectal
cancer) suggested that the combination is active as a second-line
chemotherapy in advanced pancreatic carcinoma (Correale et al,
2000).
On these bases, we have designed the present phase II clinical
trial in order to investigate the antitumour activity and toxicity of a
novel biweekly schedule of treatment combining GEM, with 5-FU
and FA (FUFA) in patients with advanced pancreatic carcinoma.
MATERIALS AND METHODS
Eligibility criteria: The inclusion criteria required a histological
diagnosis of pancreatic adenocarcinoma, an Eastern Cooperative
Oncology Group (ECOG) p2, a life expectancy of 43 months,
normal renal and hepatic function, white blood cell count
42500mm
 3, haemoglobin 49gdl
 1, platelet cell count
4100000mm
 3, and normal cardiac function. The exclusion
criteria were any major organ failure, central nervous system
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linvolvement, second tumours, or active infectious disease. The
study was approved by a local (University) ethics committee. All
patients gave their written informed consent. The study was
designed to test the hypothesis that the combination of GEM plus
FUFA is active in the treatment of pancreatic carcinoma. A
minimum of 25 patients was required to maintain an alpha and
beta error of, respectively, 0.05 and 0.2. If no clinical response
could be demonstrated in the first 10 consecutive patients, the
study was to be terminated early.
Patients received FA (100mgm
 2) followed by 5-FU (400
mg/m
 2) intravenous infusion (FUFA) on days 1–3. GEM
(1000mgm
 2) was administered on day 1 (before FA and 5-FU
infusion). The cycles were repeated every 15 days. These doses
were extrapolated from previous studies of FUFA alone or in
combination with GEM.
Clinical assessments: A complete history, physical examination,
complete blood count, and serum chemistry were performed
before the start of the treatment and repeated every month.
Complete disease staging was undertaken at baseline, and after 6-
and 12-treatment cycles by chest X-ray, computed tomography,
and ultrasound scans. Response and toxicity were assessed
according to standard World Health Organization (WHO) criteria
(World Health Organization, 1979).
Statistical analysis: Overall survival and time to progression
were calculated by performing the Kaplan-Meier curves.
RESULTS
Patient characteristics
A total of 42 patients with histologically confirmed, unresectable
pancreatic adenocarcinoma (28 males and 14 females; average age
of 61 years: range 31–81) were included in the study between
October 1999 and April 2002. In all, 15 patients underwent
palliative surgery for obstructive jaundice or duodenal obstruction
before beginning the chemotherapy. In all, 11 patients had
locoregional unresectable disease while 31 had metastatic disease
(22 with liver metastases and nine with metastases not involving
the liver).
None of the patients had received previous chemotherapy,
radiotherapy or chemoradiotherapy. Table 1 summarises their
main characteristics.
A total of 336 cycles of treatment were administered (median:
range of 8 cycles per patient: range 2–12).
Toxicity profile
The treatment seemed to be very well tolerated; no WHO grade IV
toxicity or toxic death was recorded. The most frequent side effects
involved gastroenteric (seven cases, grade II–III) or heamatolo-
gical toxicity (seven cases, grade III), none of which required
treatment discontinuation or delays. Moderate asthenia and
fatigue were reported by 10 patients during the second week of
treatment.
None of the patients experienced anaemia, increased creatinine/
blood urea nitrogen levels, or hypotension.
Response and survival
All patients were enrolled with intent to treat and were evaluable
for response. In this study, we recorded an objective response in 13
out of 42 patients (two complete (4.8%) and 11 partial responses
(26.2%)); and a disease stabilisation in 23 (55%) cases; one patient
was prematurely withdrawn from the study because of the rapid
deterioration in performance status due to very rapid progression
of disease, while five of them experienced a rapid disease
progression within the first six cycles. The time to progression
of these patients was 9.75 months (95% of confidence internal (CI)
6.88–12.62).
The treatment also appeared to have a considerable impact on
patient survival: the overall survival was in fact 13.1 months (95%
CI 9.64–16.56) with four patients alive after 42 months after the
diagnosis.
Two patients, who developed a single metastatic lesion in the
liver 6 months after the end of the chemotherapy underwent
partial hepatectomy and a further six chemotherapy cycles using
the same schedule. They are still disease free, respectively, 6 and 8
months after the metastatic resection.
DISCUSSION
The vast majority of pancreatic carcinoma patients are diagnosed
with locally advanced or metastatic disease that precludes surgical
resection and needs systemic treatment (Rosewicz and Wieden-
mann, 1997). Before GEM became available for clinical use, a large
number of trials of other drugs or drug combinations had reported
a high level of toxicity with minimal antitumour activity and no
significant gain in median survival, which ranged between 5 and 6
months even in the most optimistic studies (Mallinson et al, 1980;
Friedman et al, 1981; Cullinan et al, 1985; Palmer et al, 1994;
Lionetto et al, 1995; Evans et al, 2001). GEM was the first cytotoxic
drug to be approved in the US as a first-line treatment for
pancreatic carcinoma. It was effective in controlling cancer-related
symptoms, but still led to a low rate of objective responses, and did
not affect the median patient survival in comparison with 5-FU
alone (Burris et al, 1997). Further studies testing different schedule
of GEM administration (Ulrich-Pur et al, 2000) or combination of
GEM with other drugs such as 5-FU (Schulz et al, 1998; Berlin et al,
1998–99, 2002; Cascinu et al, 1999; Hidalgo et al, 1999; Cohen et al,
2002; Heinemann et al, 2000; Oettle and Riess, 2002), cisplatinum
(Colucci et al, 1999, Heinemann et al, 2000), adriamycin
(Scheithauer et al, 1999, Neri et al, 2002), docetaxel (Jacobs,
2002), and oxaliplatin (Louvet et al, 2002) led to higher response
rates and interesting results in terms of clinical benefit. However,
the majority of these studies also reported to have little effect on
patient median survival (range 7–8.3 months), and were all
Table 1
Characteristics Number of patients
Patients evaluable for response 42
Patients evaluable for toxicity 42
Age (years)
Median 61
Range 32–81
Sex
Male 28
Female 14
Performance status (ECOG) 0–2
Histology
Pancreatic adenocarcinoma (G2-3) 42
Stage
III 11 (26.2%)
IV 31 (73.8%)
Previous treatment
Surgery 15 (35.7%)
None
a 27 (64.3%)
Disease extension
Locoregional 11 (26.2%)
Metastatic (A+B) 31 (73.8%)
A Liver 22 (52.4%)
B No liver (bone+lung+peritoneum) 9 (1+2+6) (21.4%)
aHistological diagnosis performed by ultrasound-guided thin-needle biopsy.
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toxicity. Only one of these studies (Louvet et al, 2002) reported a
promising antitumour activity of GEMþoxaliplatin with a
response rate of 30.6%, clinical benefit improvement in 40% of
cases, and an overall survival of 9.2 months with 36% of the
patients being still alive after 1 year. The multidrug combination of
GEM with 5-FU was certainly the most investigated for the
treatment of this disease. A number of studies have, in fact, tested
the combination administering the two drugs by using different
modalities (continuous infusion, or bolus, weekly administrations,
etc.) at different doses, with or without FA. These studies reported
discordant results in terms of clinical responses, time to
progression and overall survival and some of them recorded a
high degree of therapy related toxicity (Grem, 1996; Hidalgo et al,
1997, 1999; Michel and Moore, 1997; Berlin et al, 1998–99; Schulz
et al, 1998; Cascinu et al, 1999; Ulrich-Pur et al, 2000; Cohen et al,
2002; Heinemann, 2002; Oettle and Riess, 2002). The results of the
only phase III trial comparing the weekly schedules of 5-FU/GEM
with GEM alone did not show any advantage of the combination in
terms of overall survival, progression-free survival, or response
rate (Berlin et al, 2002).
The majority of these studies combined the two fluoropyrimi-
dines on empiric clinical bases, and this may have generated the
large discordance in the results; in our study, we have instead
designed a novel schedule of a combination aimed to maximise the
antitumour efficacy of GEMþFUFA, and to reduce the occurrence
of side effects taking advantage of the results of previous
preclinical studies, pharmacokinetic analyses, and considering
the possibility of administering the drugs on an outpatient basis at
a low cost. In the first place in fact, our preclinical data suggested
that GEM given before 5-FU produces synergistic antitumour
(Correale et al, 2000) and proapoptotic (Correale et al, unpub-
lished results) activity in colon and pancreas carcinoma cell lines
in vitro, in the second instance, we also considered that GEM
pretreatment enhances the systemic exposure of 5-FU in cancer
patients by increasing its area under the curve (AUC) and reducing
its clearance (Correale et al, 2003). We also considered the results
of previous phase I–II clinical trials testing the first GEMþFUFA
combination in patients with various gastroenteric carcinomas,
which suggested a significant antitumour activity in patients with
pancreatic carcinoma unfortunately hampered by a high level of
gastroenteric toxicity mainly due to the 5-day schedule of 5-FU
administration and the weekly administration of GEM (Correale
et al, 1999, 2000). In the novel biweekly schedule, therefore the
dose intensity of GEM remained unchanged, and although
distributed in two consecutive weeks, the monthly 5-FU dose
intensity was increased. With these modifications, our new
schedule of treatment definitely improved the patients’ quality of
life during the treatment, significantly reduced the toxicity of the
combination, and led to a significant rate of objective responses,
with a prolonged time to progression and overall survival. These
positive results do not seem to be due to a better selection of the
patients because, at the time of the enrolment, 11 patients (26.2%)
had very advanced local–regional disease, 22 (52.4%) had liver
metastases and nine had metastatic sites. It is interesting to note
that a number of the patients are still alive 36 months after the
diagnosis, that eight patients with a partial response had liver
involvement, and two patients subsequently underwent successful
partial hepatectomy for liver metastases and are still alive and
disease free 18 months later. It is notoriously difficult to compare
the median survival data of early phase II trials but, given the
clinical results and the toxicity of the studies described above, our
findings seem to be very promising. To what extent these patients
will benefit in terms of survival from the biweekly treatment with
GEM and FUFA in comparison with GEM alone or no treatment at
all awaits the results of future prospective randomised trials.
REFERENCES
Allegra CJ, Grem JL (1997) Antimetabolite. In Cancer, Principles & Practice
of Oncology, De Vita Jr TV, Hellman S, Rosenberg SA (eds) (5th ed.) pp
432–452. Lipponcott William & Wilkins: Philadelphia
Bakkevold KE, Arnesjo B, Kambestad B (1992) Carcinoma of the pancreas
and papilla of Vater: presenting symptoms, signs, and diagnosis related
to stage and tumour site. A prospective multicentre trial in 472 patients.
Norwegian Pancreatic Cancer Trial. Scand J Gastroenterol 27: 317–325
Berlin JD, Alberti DB, Arzoomanian RZ, Feierabend CA, Simon KJ, Binger
KA, Mamocha RM, G (1998–99) A phase I study of gemcitabine, 5-
fluorouracil and leucovorin in patients with advanced, recurrent, and/or
metastatic solid tumours. Invest New Drugs 16(4): 325–330
Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB (2002)
Phase III study of gemcitabine in combination with fluorouracil versus
gemcitabine alone in patients with advanced pancreatic carcinoma:
Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:
3270–3275
Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos
JP (1995) Treatment and survival in 13,560 patients with pancreatic
cancer, and incidence of the disease, in the West Midlands: an
epidemiological study. Br J Surg 82: 111–115
Burris III HA, Moore M, Andersen J, Green MR, Rothenberg ML, Modiano
MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr
FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and
clinical benefit gemcitabine as first line therapy for patients with
advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6): 2403–
2413
Cascinu S, Silva RR, Barni S, Labianca R, Frontini L, Piazza E, Pancera G,
Giordani P, Giuliodori L, Pessi MA, Fusco V, Luporini G, Cellerino R,
Catalano G (1999) A combination of gemcitabine and 5-fluorouracil in
advanced pancreatic cancer, a report from the Italian Group for the
Study of Digestive Tract Cancer (GISCAD). Br J Cancer 80: 1595–1598
Chu E, Mota AC, Fogarasi MC (2001) Antimetabolite. In Cancer, Principles
& Practice of Oncology, De Vita Jr TV, Hellman S, Rosenberg SA (eds)
(6th ed.) pp 388–411. Lippincott William & Wilkins: Philadelphia
Cohen SJ, Pinover WH, Watson JC, Meropol NJ (2002) Pancreatic cancer.
Curr Treat Options Oncol 1: 375–386
Colucci G, Riccardi F, Giuliani F, Lopez M, Gebbia V, Uomo G, Biglietto M,
Cigolari S, Borsellino N, Paoletti G, Maiello F, Gebbia N (1999)
Randomized trial of gemcitabine alone or with cisplatin in advanced
pancreatic cancer: phase II multicenter study of the Southern Italy
Oncology Group. Proc Am Soc Clin Oncol 18: 250a
Correale P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, Messinese S,
Sabatino M, Roviello F, Pinto E, Francini G, Giorgi G. (2003)
Gemcitabine increases 5-fluorouracil systemic exposure in advanced
cancer patients: pharmacokinetic considerations. Eur J Cancer, in press
Correale P, Cerretani D, Petrioli R, Marsili S, Giorgi G, Francini G (2000)
Gemcitabine (dFdC) and 5 fluorouracil (5FU) in the treatment of patients
with pancreas and colo-rectal carcinoma: a clinical and pharmacological
study. ICACT 10th International Congress on anti-Cancer treatment
January 31–February 3 2000, Paris, France, abs. n. I-293
Correale P, Cerretani D, Petrioli R, Marsili S, Pozzessere D, Giorgi G,
Francini G (1999) Gemcitabine (dFdC) affects 5-fluorouracil (5FU)
Pharmaco kinetics in cancer patients. Proc Annu Meet Am Ass Cancer
Res 40: 2546
Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK et al
(1985) A comparison of three chemotherapeutic regimens in the
treatment of advanced pancreatic and gastric carcinoma. Fluorouracil
vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and
mitomycin. JAMA 253: 2061–2067
Evans DB, Abbruzzese JL, Willett CG (2001) Cancer of the pancreas. In
Cancer, Principles & Practice of Oncology, De Vita Jr TV, Hellman S,
Rosenberg SA (eds) (6th ed.) pp 1126–1148. Lippincott William &
Wilkins: Philadelphia
Pancreas carcinoma therapy with biweekly gemcitabine, FA/5-FU
P Correale et al
241
British Journal of Cancer (2003) 89(2), 239–242 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lFriedman MA, Cassidy MJ, Hannigan JF, Gribble M, Torti FM, Reynolds RD
(1981) Phase III study of adriamycin+5-FU vs BCNU+adriamycin+ftor-
afur for patients with advanced pancreatic cancer. Proc Am Assoc Cancer
Res and Am Soc Clin Oncol 22: 156
Grem JL (1996) 5-Fluoropyrimidines. In Cancer Chemotherapy and
Biotherapy: Principles and Practice, Chabner BA, Longo DL (eds) (2nd
ed.) pp 149–163. Lippincot William & Wilkins: Philadelphia
Jacobs AD (2002) Gemcitabine-based therapy in pancreas cancer:
Gemcitabine-docetaxel and other novel combinations. Cancer 95:
923–927
Heinemann V (2002) Present and future treatment of pancreatic cancer.
Semin Oncol 29: 23–31
Heinemann V, Wilke H, Mergenthaler HG, Clemens M, Konig H, Illiger HJ,
Arning M, Schalhorn A, Possinger K, Fink U (2000) Gemcitabine and
cisplatin in the treatment of advanced and metastatic pancreatic cancer.
Ann Oncol 11: 1399–1403
Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz Puente M, Hitt R,
Alonso S, Cortes-Funes H (1999) Phase I–II study of gemcitabine and
fluorouracil as a continuous infusion in patients with pancreatic cancer. J
Clin Oncol 17(2): 585–592
Hidalgo M, Paz-Ares L, Hitt R, Cortes-Funes H (1997) Phase I–II study of
gemcitabine combined with continuous infusion 5-fluorouracil as first-
line chemotherapy in locally advanced and metastatic pancreatic cancer.
Proc Am Soc Clin Oncol 16: 290a
Lionetto R, Pugliese V, Bruzzi P, Rosso R (1995) No standard treatment
is available for advanced pancreatic cancer. Eur J Cancer 31A(6):
882–887
Louvet C, Andre T, Dledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E,
Flesch M, Cvitkovic E, de Gramont A (2002) Gemcitabine combined with
oxaliplatin in advanced pancreatic adenocarcinoma: final results of a
GERCOR multicenter phase II study. J Clin Oncol 20(6): 512–518
Mallinson CN, Rake MO, Cocking JB, Fox CA, Cwynarski MT, Diffey BL,
Jackson GA, Hanley J, Wass VJ (1980) Chemotherapy in pancreatic
cancer: results of a controlled, prospective, randomized, multicentre
trial. Br Med J 281: 1589–1591
Michael M, Moore M (1997) Clinical experience with gemcitabine in
pancreatic carcinoma. Oncology(Hunting) 11(11): 1615–1622; discussion
1622, 1625–1627
Neri B, Cini G, Doni L, Fulignati C, Turrini M, Pantalone D, Mini E, De
Luca Cardillo C, Fioretto LM, Ribecco AS, Moretti R, Scatizzi M, Zocchi
G, Quattrone A (2002) Weekly gemcitabine plus Epirubicin as effective
chemotherapy for advanced pancreatic cancer: a multicenter phase II
study. Br J Cancer 87(5): 497–501
Oettle H, Riess H (2002) Gemcitabine in combination with 5-fluorouracil
with or without folinic acid in the treatment of pancreatic cancer. Cancer
95: 912–922
Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC (1994)
Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br
J Surg 81: 882–885
Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: Preclinical
pharmacology and mechanisms of action. Semin Oncol 23: 3–15
Rocha Lima CM, Centeno B (2002) Update on pancreatic cancer. Curr Opin
Oncol 14: 424–430
Rosewicz S, Wiedenmann B. (1997) Pancreatic carcinoma. Lancet 349:
485–489
Scheithauer W, Kornek GV, Raderer M, Hejna M, Valencak J, Miholic J,
Kovats E, Lang F, Funovics J et al (1999) Phase II trial of gemcitabine,
epirubicin and granulocyte colony-stimulating factor in patients with
advanced pancreatic adenocarcinoma. Br J Cancer 80: 1797–1802
Schulz L, Schalhorn A, Wilmanns W, Heinemann V (1998) Synergistic
interaction of dFdC and 5-FU in colon cancer cells. Proc Am Soc Clin
Oncol 17: 251a
Silverberg E, Boring CC, Squires TS (1990) Cancer statistics. CA Cancer J
Clin 40: 9–26
Ulrich-Pur H, Kornek GV, Raderer M, Haider K, Kwasny W, Depisch D,
Greul R, Schneeweiss B, Krauss G, Funovics J, Scheithauer W (2000) A
phase II trial of biweekly high dose gemcitabine for patients with
metastatic pancreatic adenocarcinoma. Cancer 88: 2505–2511
World Health Organization (1979) WHO Handbook for Reporting Results of
Cancer Treatment. Geneve: World Health Organization
Pancreas carcinoma therapy with biweekly gemcitabine, FA/5-FU
P Correale et al
242
British Journal of Cancer (2003) 89(2), 239–242 & 2003 Cancer Research UK
C
l
i
n
i
c
a
l